Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224255 | 0.92 | LMNA (0.51) | RIPK1HTR2CLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL5777914 | 0.91 | LMNA (0.50) | RIPK1HTR2CLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL15924140 | 0.88 | RIPK1 (0.43) | RIPK1HTR2CLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL15924949 | 0.85 | FEN1 (0.45) | RIPK1HTR2CLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL20627556 | 0.85 | RIPK1 (0.41) | RIPK1HTR2CLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL5133567 | 0.85 | RIPK1 (0.46) | RIPK1HTR2CPDE5APDE4APDE4B | |
| SCHEMBL7103147 | 0.82 | RIPK1 (0.44) | RIPK1HTR2C | |
| SCHEMBL18615875 | 0.81 | LMNA (0.51) | LMNAKMT2ASMN1; SMN2HPGDHTT | |
| SCHEMBL18586429 | 0.81 | LMNA (0.51) | LMNAKMT2ASMN1; SMN2HPGDHTT | |
| SCHEMBL21949703 | 0.81 | LMNA (0.51) | LMNAKMT2ASMN1; SMN2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| CN-108558889-A | Bu Luomo structural domain inhibitor | 赛尔基因昆蒂赛尔研究公司 | 2018-09-21 | — | — | CN | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| CN-1263751-C | Novel compounds | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| CN-1541214-A | Novel compounds | — | 2004-10-27 | — | — | CN | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | RIPK1 4532/4885HTR2C 186/4885LMNA 3591/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | RIPK1 4424/4885HTR2C 284/4885LMNA 3431/4885 |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | RIPK1 1586/4885HTR2C 1842/4885LMNA 1883/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | RIPK1 1586/4885HTR2C 1842/4885LMNA 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.